Agent-based modeling of cellular dynamics in adoptive cell therapy.

Area of Science:

• Immunology
• Computational Biology
• Oncology

Background:

• Adoptive cell therapies (ACT) show promise for cancer treatment by harnessing tumor-immune interactions.
• Understanding the molecular mechanisms and cellular properties for broad clinical benefit in CAR-NK cell therapies remains a challenge.
• In vitro and in vivo studies are resource-intensive and limited in scope.

Purpose of the Study:

• To develop an in silico approach for simulating tumor-immune dynamics in ACT.
• To identify critical cellular properties and strategies for optimizing ACT efficacy.
• To provide a platform for systematic in silico trials to guide ACT development.

Main Methods:

• Development of ABMACT (Agent-Based Model for Adoptive Cell Therapy), an agent-based modeling (ABM) framework.
• Simulation of heterogeneous tumor-immune ecosystems with virtual cells based on experimental and patient omics data.
• Application of the model in various therapeutic contexts to analyze ACT dynamics.

Main Results:

• ABMACT effectively simulates the continuous course and dynamics of evolving tumor-immune ecosystems.
• Key factors for optimal ACT efficacy identified include enhanced immune cellular proliferation, cytotoxicity, and serial killing capacity.
• The model demonstrates potential for predicting optimal treatment strategies.

Conclusions:

• ABMACT offers a powerful in silico tool to complement experimental approaches in ACT research.
• Systematic in silico trials using ABMACT can accelerate ACT product development.
• The findings highlight crucial cellular mechanisms for improving cancer immunotherapy outcomes.